All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Period1 (Per1), period2 (Per2), period3 (Per3), cryptochrome1 (Cry1), cryptochrome2 (Cry2), aryl hydrocarbon receptor nuclear translocator-like protein 1 (Bmal1), neuronal PAS domain protein 2 (Npas2) and circadian locomoter output cycles protein kaput (CLOCK) genes are the eight core circadian clock genes that generate and maintain circadian rhythms in many physiologic processes \[[@pone.0233508.ref001], [@pone.0233508.ref002]\]. Per1, Per2 and Per3 were reported to play an important role in regulating cancer cell growth, proliferation and apoptosis \[[@pone.0233508.ref003], [@pone.0233508.ref004], [@pone.0233508.ref005]\]. Cry1 and Cry2 acted as transcriptional regulators and checkpoint proteins for cancer cell proliferation and cell cycle control \[[@pone.0233508.ref006], [@pone.0233508.ref007]\]. Bmal1 and Npas2 could regulate cancer cell proliferation and invasion through suppressing the transcription of c-Myc\[[@pone.0233508.ref008], [@pone.0233508.ref009]\]. CLOCK might interact with HIF-1α/ Bmal1 and activate VEGF to stimulate tumor angiogenesis and metastasis \[[@pone.0233508.ref010]\]. These eight circadian clock genes take part in the carcinogenesis and development of many cancers. Recent studies demonstrated that disrupted expression of these genes was associated with poor progression and prognosis of cancers. For example, low Per1, Per2 and Per3 expressions in different cancers were found to correlate with worse histological grade and poor prognosis \[[@pone.0233508.ref003], [@pone.0233508.ref005], [@pone.0233508.ref011]--[@pone.0233508.ref022]\]; Cry2 was reported downregulated in breast and pancreatic cancer and its low expression was associated with higher tumor grade and shorter survival time \[[@pone.0233508.ref023], [@pone.0233508.ref024]\]; reduced Bmal1 and CLOCK expressions were confirmed to result in poor outcome of colon, pancreatic, kidney, head and neck cancers \[[@pone.0233508.ref015], [@pone.0233508.ref025], [@pone.0233508.ref026]\]; low Npas2 expression was also found to be related with worse overall survival (OS) in colorectal and breast cancers \[[@pone.0233508.ref009], [@pone.0233508.ref027]\]. However, several other studies showed that low expression of these genes was not correlated with the prognosis of cancers. For example, low Per1 expression in lung cancer was not related to prognosis \[[@pone.0233508.ref028]\]; downregulated Per2 and Per3 expression were not correlated with gastric and colorectal cancer (CRC) prognosis \[[@pone.0233508.ref029], [@pone.0233508.ref030]\]; low Cry1 expression was not an independent prognostic factor for ovarian cancer \[[@pone.0233508.ref031]\];reduced expression of Bmal1 and CLOCK were not associated with lung cancer survival and CRC outcomes\[[@pone.0233508.ref028], [@pone.0233508.ref030]\]; Moreover, some studies even implied that overexpression of some of these genes was associated with unfavorable prognosis in patients with cancers. For example, Cry1 and Cry2 overexpression was associated with poor OS in gastric cancer and CRC \[[@pone.0233508.ref029], [@pone.0233508.ref032], [@pone.0233508.ref033]\]; Npas2 was frequently upregulated in hepatocellular carcinoma (HCC) and its overexpression significantly contributed to poor prognosis of HCC patients \[[@pone.0233508.ref034]\]. The clinicopathological and prognostic value of these circadian clock genes in cancers remains controversial and inconclusive. Therefore, we conducted this meta-analysis by integrating published data and online database to clarify the influence of low expression of these seven circadian clock genes on the clinicopathological features and prognosis of different cancers.

Materials and methods {#sec006}
=====================

1. Literature search {#sec007}
--------------------

We systematically searched through the databases (Cochrane Central Register of Controlled Trials, Embase, EBSCO, Ovid, PubMed, Science Direct and Wiley Online Library, China National Knowledge Infrastructure (CNKI) and Wan Fang database) to obtain relevant articles that were published before 1 January 2020. The following terms and phrases were used as search criteria: 'circadian clock gene' or 'period1 (Per1)' or 'period2 (Per2)', or 'period3 (Per3)' or 'cryptochrome1 (Cry1)' or 'cryptochrome2 (Cry2)' or 'aryl hydrocarbon receptor nuclear translocator-like protein 1 (Bmal1)' or 'neuronal PAS domain protein 2 (Npas2) ' or 'circadian locomoter output cycles protein kaput (CLOCK)' and 'neoplasm' or 'tumor' or 'cancer', 'carcinoma' and 'prognosis' or 'overall survival (OS)' or 'mortality' or 'clinic outcome' or 'clinicopathological feature' or 'odd ratio (OR)' or 'hazard ratio (HR)'. The title and abstract of each study obtained in the search was scanned to exclude any clearly irrelevant ones. The remaining articles were reviewed, analyzed, evaluated to determine whether they contained information on the topic of interest. The reference lists of these articles with information on the topic were also reviewed for additional pertinent studies.

2. Inclusion and exclusion criteria {#sec008}
-----------------------------------

Inclusion criteria were as follows: (1) patients diagnosed with cancers; (2) immunohistochemical (IHC) analysis, quantitative PCR, RNA-Sequence analysis and in situ hybridization detection of circadian clock genes expression in tissues; (3) relationships between abnormal expression of circadian clock genes and clinicopathological features or prognostic indicators that were evaluated; (4) odds ratio (OR), hazard ratio (HR) and 95% confidence intervals (CI) that could be obtained directly or indirectly calculated based on the data provided in the graphics and tables; (5) only the newest studies were retained if the data were repeated in different studies and (6) studies in English or Chinese.

Exclusion criteria were as follows: (1) cell or animal studies, letters, case reports, reviews and meta-analyses; (2) articles with similar content or those with small sample sizes (≤ 10) and (3) articles with language barriers.

3. Data extraction {#sec009}
------------------

The articles that met the criteria were reviewed by two independent investigators (ZhimoWang and HongLv) and extracted data on author, year of publication, nationality, sample size, patient age, detection method, clinical stage and pathological degree. Discrepancies in terms of data extraction were resolved by discussion among all the authors.

4. Statistical analysis {#sec010}
-----------------------

The ORs and 95%CI between aberrant circadian clock genes expression and clinicopathological indexes were calculated from the original data in articles using statistical software. The prognostic effects of low circadian clock genes expression were detected by merging the HRs and 95%CI of the included literatures using the forest plot. The HRs and 95% CI values either came from direct extraction of the original text or indirect extraction of survival curve through Engauge Digitizer version 4.1 (<https://sourceforge.net/projects/digitizer/>) \[[@pone.0233508.ref035]\].

Heterogeneity was measured by *Q* statistics as follows: no heterogeneity: 0\<*Ι*^2^\<25%; low heterogeneity: 25%≤*Ι*^2^\<50%; moderate heterogeneity: 50%≤*Ι*^2^\<75%; high heterogeneity: 75%≤*Ι*^2^≤100%. A random effects model was used to pool HRs and ORs with or without significant heterogeneity. An *I*^2^*\<*50% was considered acceptable, and a P value*\>*0.10 signified an acceptable degree of homogeneity. Sensitivity and subgroup analysis for the source of the heterogeneity was performed according to publication year, population, detecting method, pathological types and patient number. Publication bias was detected by Begg's funnel plot and Egger's test. A two-sided *Ρ* value \<0.05 was considered to indicate statistical significance. Statistical analyses were carried out with Stata SE 12.0, Engauge, Microsoft Office 2007.

Results {#sec011}
=======

1. Eligible studies {#sec012}
-------------------

A total of 755 articles were identified from a search of the included databases using the search strategy as described in [Fig 1](#pone.0233508.g001){ref-type="fig"}. 682 articles were excluded through reviewing the titles and abstracts. The remaining 74 articles were then fully examined for their fit with the current meta-analysis, and a further 38 articles were excluded because they met one or more of the exclusion criteria. The final 36 studies \[[@pone.0233508.ref003], [@pone.0233508.ref006], [@pone.0233508.ref009], [@pone.0233508.ref011]--[@pone.0233508.ref017], [@pone.0233508.ref019], [@pone.0233508.ref022], [@pone.0233508.ref024], [@pone.0233508.ref025], [@pone.0233508.ref027]--[@pone.0233508.ref030], [@pone.0233508.ref032]--[@pone.0233508.ref034], [@pone.0233508.ref036]--[@pone.0233508.ref050]\] with 7476 cases were included in our meta-analysis ([Fig 1](#pone.0233508.g001){ref-type="fig"}). The fundamental features of the included studies were presented in [Table 1](#pone.0233508.t001){ref-type="table"} and [Fig 2](#pone.0233508.g002){ref-type="fig"}. Among the 36 studies, 25 studies \[[@pone.0233508.ref003], [@pone.0233508.ref006], [@pone.0233508.ref009], [@pone.0233508.ref011]--[@pone.0233508.ref017], [@pone.0233508.ref019], [@pone.0233508.ref022], [@pone.0233508.ref028], [@pone.0233508.ref030], [@pone.0233508.ref033], [@pone.0233508.ref036]--[@pone.0233508.ref041], [@pone.0233508.ref043], [@pone.0233508.ref046], [@pone.0233508.ref047], [@pone.0233508.ref050]\] assessed the association between low circadian clock genes expression and clinicopathological features in patients with cancers, and 22 studies \[[@pone.0233508.ref003], [@pone.0233508.ref006], [@pone.0233508.ref012]--[@pone.0233508.ref015], [@pone.0233508.ref019], [@pone.0233508.ref022], [@pone.0233508.ref024], [@pone.0233508.ref027], [@pone.0233508.ref028], [@pone.0233508.ref029], [@pone.0233508.ref030], [@pone.0233508.ref032], [@pone.0233508.ref033], [@pone.0233508.ref034], [@pone.0233508.ref041], [@pone.0233508.ref042], [@pone.0233508.ref047]--[@pone.0233508.ref050]\] investigated the relationship between low expression of circadian clock genes and OS in multiple cancers.

![Flow diagram of the study selection process.](pone.0233508.g001){#pone.0233508.g001}

![The percentage of different types of cancer included for the meta-analysis.](pone.0233508.g002){#pone.0233508.g002}

10.1371/journal.pone.0233508.t001

###### Characteristics of studies included for the meta-analysis.

![](pone.0233508.t001){#pone.0233508.t001g}

  Author                                            Year   Population   Cancer type                        Number of patients   Gender (Male/Female)   Detection method         Gene (Low expression, high expression)
  ------------------------------------------------- ------ ------------ ---------------------------------- -------------------- ---------------------- ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------
  Winter SL, et al.\[[@pone.0233508.ref036]\]       2007   Canadian     Breast cancer                      34                   0/34                   Quantitative PCR         Per1 (16, 10)
  Kuo SJ, et al. \[[@pone.0233508.ref037]\]         2009   Chinese      Breast cancer                      53                   0/53                   Immunohistochemistry     Per1 (26, 27)
  Climent J, et al.\[[@pone.0233508.ref038]\]       2010   Chinese      Breast cancer                      203                  0/203                  Quantitative PCR         Per3 (36, 167)
  Zhang YB, et al. \[[@pone.0233508.ref011]\]       2015   Chinese      Breast cancer                      60                   0/60                   Immunohistochemistry     Per1 (19, 41), Per2 (13, 47)
  Mao Y, et al. \[[@pone.0233508.ref024]\]          2015                Breast cancer                      737                  0/737                  Microarray               Cry2
  Yi C, et al. \[[@pone.0233508.ref027]\]           2010   American     Breast cancer                      287                  0/287                  Quantitative PCR         Npas2 (94, 193)
  Zhao N, et al. \[[@pone.0233508.ref040]\]         2013   Chinese      Buccal squamous cell carcinoma     38                   16/22                  Immunohistochemistry     Per1 (6, 32)
  Yang C, et al. \[[@pone.0233508.ref014]\]         2018   Chinese      Cervical squamous cell carcinoma   239                  0/239                  IlluminaHiSeq-miRNASeq   Per1 (138, 101)
  Eisele L, et al. \[[@pone.0233508.ref045]\]       2009   German       Chronic lymphocytic leukemia       116                  82/34                  Quantitative PCR         Cry1 (62, 46)
  Wang X, et al. \[[@pone.0233508.ref022]\]         2012   Chinese      Colon cancer                       203                  86/117                 Immunohistochemistry     Per3 (36, 167)
  Wang Y, et al. \[[@pone.0233508.ref041]\]         2015   Chinese      Colon cancer                       203                  86/117                 Immunohistochemistry     Per1 (21, 182)
                                                                        Colon cancer                       454                  240/214                RNA-Seq analysis         CLOCK (258, 196)
  Oshima T, et al. \[[@pone.0233508.ref030]\]       2011   Japanese     Colorectal cancer                  202                  110/92                 Quantitative PCR         Per1 (101, 101), Per2 (101, 101), Per3 (101, 101), Cry1 (101, 101), Cry2 (101, 101), Baml1 (101, 101), CLOCK(101, 101)
  Wu S, et al. \[[@pone.0233508.ref042]\]           2016   Chinese      Colorectal cancer                  214                                         HiSeq platform           Per1 (82, 132)
  Hasakova K, et al. \[[@pone.0233508.ref044]\]     2018   Slovakian    Colorectal cancer                  61                   38/23                  Quantitative PCR         Per2 (31, 30), Cry1 (31, 30), Cry2 (31, 30)
  Yu H, et al. \[[@pone.0233508.ref032]\]           2013   Chinese      Colorectal cancer                  168                  89/79                  Quantitative PCR         Cry1 (67, 101)
  Fang L, et al. \[[@pone.0233508.ref033]\]         2015   Chinese      Colorectal cancer                  289                  147/142                Immunohistochemistry     Cry2 (165, 124)
  Xue X, et al. \[[@pone.0233508.ref009]\]          2014   Chinese      Colorectal cancer                  108                  59/49                  Quantitative PCR         Npas2 (54, 54)
  Yang SF, et al. \[[@pone.0233508.ref047]\]        2016   Chinese      Colorectal cancer                  120                  79/41                  Quantitative PCR         Npas2 (97, 23)
  Zeng Z, et al. \[[@pone.0233508.ref048]\]         2014   Chinese      Colorectal cancer                  82                                          Immunohistochemistry     Baml1 (46, 36)
  Wang Y, et al. \[[@pone.0233508.ref016]\]         2011   Chinese      Colorectal carcinoma               38                   18/20                  Immunohistochemistry     Per2 (24, 14)
  Momma T, et al. \[[@pone.0233508.ref013]\]        2017   Japanese     Colorectal carcinoma               51                   32/19                  In situ hybridization    Per1 (27, 24), Per2 (25, 26), CLOCK(30, 21)
  Liu HJ, et al. \[[@pone.0233508.ref046]\]         2015   Chinese      Gastrointestinal adenocarcinoma    63                   40/23                  Immunohistochemistry     Cry1 (37, 26)
  Hu ML, et al. \[[@pone.0233508.ref029]\]          2014   Chinese      Gastric cancer                     29                   20/9                   Quantitative PCR         Per1, Per3
  Zhao H, et al. \[[@pone.0233508.ref012]\]         2014   Chinese      Gastric cancer                     246                  181/65                 Immunohistochemistry     Per1 (143, 103), Per2 (160, 86)
  Ding HB, et al. \[[@pone.0233508.ref043]\]        2018   Chinese      Gastric cancer                     106                  68/38                  Immunohistochemistry     Per1 (4, 102), Cry1 (58, 48)
  Yuan P, et al. \[[@pone.0233508.ref034]\]         2017   Chinese      Hepatocellular carcinoma           217                                         Quantitative PCR         Npas2 (108, 109)
  Li B, et al. \[[@pone.0233508.ref050]\]           2018   Chinese      Hepatocellular carcinoma           158                  143/15                 Western blot analysis    CLOCK(79, 79)
  Qiu MJ, et al. \[[@pone.0233508.ref015]\]         2019   Chinese      Kidney cancer                      530                  344/186                RNA-Seq analysis         Per1 (338, 192), Per2 (323, 204), Per3 (308, 219), Cry2 (302, 229), Npas2 (320,207), CLOCK (283, 247)
                                                                        Liver cancer                       371                  250/121                RNA-Seq analysis         Cry2 (219, 151), Npas2 (230, 141)
  Qiu MJ, et al. \[[@pone.0233508.ref028]\]         2019   Chinese      Lung adenocarcinoma                500                  230/270                RNA-Seq analysis         Per1 (367, 133), Per2 (333, 167), Per3 (333, 167), Cry1 (298, 202), Cry2 (333, 167), Npas2 (309, 191), Baml1 (310, 190), CLOCK(324, 176)
                                                                        Lung squamous cell carcinoma       494                  366/128                RNA-Seq analysis         Per1 (326, 168), Per2 (318, 167), Per3 (318, 176), Cry1 (270, 224), Cry2 (293, 201), Npas2 (292, 202), Baml1 (291, 203), CLOCK(332,162)
  De Assis LVM, et al. \[[@pone.0233508.ref049]\]   2018   American     Melanoma                           340                                         RNA-Seq analysis         Baml1 (170, 170)
  Chi C, et al. \[[@pone.0233508.ref017]\]          2013   Chinese      Non-small cell lung cancer         60                   38/22                  Immunohistochemistry     Per2 (17, 43)
  Liu B, et al. \[[@pone.0233508.ref003]\]          2014   Chinese      Non-small cell lung cancer         130                  75/55                  Immunohistochemistry     Per1 (44, 86), Per2 (53, 77), Per3 (48, 82)
  Chen R, et al. \[[@pone.0233508.ref039]\]         2012   Chinese      Oral squamous cell carcinoma       41                   24/17                  Immunohistochemistry     Per1 (7, 34)
  Xiong H, et al. \[[@pone.0233508.ref019]\]        2018   Chinese      Oral squamous cell carcinoma.      40                   25/15                  Quantitative PCR         Per2 (24, 16)
  Tokunaga H, et al. \[[@pone.0233508.ref031]\]     2008   Japanese     Ovarian cancer                     104                  0/104                  Quantitative PCR         Cry1
  Li W, et al. \[[@pone.0233508.ref025]\]           2016   Chinese      Pancreatic ductal adenocarcinoma   87                   51/36                  Immunohistochemistry     Baml1 (61, 26)

2. Circadian clock genes expression and clinicopathological features of cancers {#sec013}
-------------------------------------------------------------------------------

The correlation between low expression of circadian clock genes and clinicopathological features was exhibited in [Table 2](#pone.0233508.t002){ref-type="table"} and Figs [3](#pone.0233508.g003){ref-type="fig"} and [4](#pone.0233508.g004){ref-type="fig"} as follows. The pooled ORs indicated that the low expressions of Per1, Per2, Per3 and Npas2 were significantly related with poor differentiation (Per1: OR=2.30, 95%CI: 1.36∼3.87,=0.002; Per2: OR=2.41, 95%CI: 1.53∼3.79, *Ρ*\<0.001; Per3: OR=2.50, 95%CI: 1.10∼5.66, *Ρ*=0.001 and Npas2: OR=1.89, 95%CI: 1.47∼2.43, *Ρ*\<0.001), with no heterogeneity to high heterogeneity among studies. Furthermore, we also found that low expression of Per1 was obviously correlated with deeper depth of invasion (OR=2.12, 95%CI: 1.62∼2.77, *Ρ*\<0.001; *Ι*^2^=28.8%) and low Per2 expression was significantly associated with more advanced TNM stage (OR=3.47, 95%CI: 1.88∼6.42, *Ρ*\<0.001; *Ι*^2^=74.8) and more lymph node metastasis (OR=2.35, 95%CI: 1.35∼4.11, *Ρ*=0.003; *Ι*^2^=79.4). Therefore, although heterogeneity existed, these pooled results suggested that low expressions of Per1, Per2, Per3 and Npas2 might play important roles in the development and progression of cancers.

![Forrest plot of odds ratio (OR) for the association of low Per1 (A), Per2 (B), Per3 (C) and Npas2 (D) expression and cancer differentiation.](pone.0233508.g003){#pone.0233508.g003}

![Forrest plot of odds ratio (OR) for the association of low Per1 expression and depth of invasion (A), low Per2 expression and lymph node metastasis (B) and TNM stage (C).](pone.0233508.g004){#pone.0233508.g004}

10.1371/journal.pone.0233508.t002

###### Main meta-analysis results of association between low circadian clock genes expression and clinicopathological features in cancers.

![](pone.0233508.t002){#pone.0233508.t002g}

  Circadian clock gene                     Clinicopathological parameters         No. of studies   No. of patients      Pooled OR(95%CI)    Zvalue    P-value   Heterogeneity   Publication bias           
  ---------------------------------------- -------------------------------------- ---------------- -------------------- ------------------- --------- --------- --------------- ------------------ ------- -------
  Per1                                     Differentiation (Moderate+Well/Poor)   11               1588                 2.30 (1.36, 3.87)   3.13      0.002     64.7            0.002              1.000   0.832
  Clinical Stage (I+II/III+IV)             7                                      692              1.85 (0.85, 4.00)    1.56                0.120     84.6      \<0.001         0.230              0.168   
  Depth of invasion (T1+T2/T3+T4)          7                                      911              2.12 (1.62, 2.77)    5.49                \<0.001   28.8      0.209           0.368              0.601   
  Lymph node metastasis (Absent/Present)   9                                      1051             1.98 (0.77, 5.09)    1.42                0.155     91.0      \<0.001         0.251              0.311   
  Tumor size (\<5CM/≥5CM)                  5                                      639              0.91 (0.60, 1.36)    0.48                0.630     53.0      0.075           0.806              0.301   
  Per2                                     Differentiation (Moderate+Well/Poor)   9                1357                 2.41 (1.53, 3.79)   3.78      \<0.001   68.3            0.001              0.754   0.525
  Clinical Stage (I+II/III+IV)             4                                      397              3.87 (0.40, 37.23)   1.17                0.241     96.7      \<0.001         0.734              0.623   
  Depth of invasion (T1+T2/T3+T4)          6                                      707              1.88 (0.75, 4.74)    1.35                0.178     89.5      \<0.001         1.000              0.847   
  TNM (I + II/III + IV)                    4                                      758              3.47 (1.88, 6.42)    3.98                \<0.001   74.8      0.008           1.000              0.472   
  Lymph node metastasis (Absent/Present)   7                                      767              2.35 (1.35, 4.11)    3.00                0.003     79.4      \<0.001         0.548              0.391   
  Tumor size (\<5CM/≥5CM)                  3                                      358              0.69 (0.33, 1.42)    1.01                0.314     68.6      0.041           0.296              0.150   
  Per3                                     Differentiation (Moderate+Well/Poor)   4                1065                 2.50 (1.10, 5.66)   2.19      0.029     81.5            0.001              0.734   0.280
  Depth of invasion (T1+T2/T3+T4)          3                                      535              2.45 (0.78, 7.89)    1.54                0.124     86.1      0.001           0.296              0.204   
  Lymph node metastasis (Absent/Present)   3                                      535              1.50 (0.81, 2.79)    1.29                0.197     61.2      0.076           0.296              0.173   
  Cry1                                     Differentiation (Moderate+Well/Poor)   4                539                  0.89 (0.47, 1.68)   0.36      0.722     52.8            0.095              0.734   0.580
  Depth of invasion (T1+T2/T3+T4)          4                                      539              0.86 (0.22, 3.26)    0.22                0.825     85.5      \<0.001         0.734              0.319   
  Lymph node metastasis (Absent/Present)   4                                      539              0.55 (0.29, 1.03)    1.87                0.062     62.9      0.044           0.734              0.453   
  Tumor size (\<5CM/≥5CM)                  4                                      539              1.10 (0.77, 1.56)    0.52                0.603     0.0       0.464           0.734              0.326   
  Cry2                                     Differentiation (Moderate+Well/Poor)   4                1392                 1.35 (0.84, 2.15)   1.24      0.214     71.6            0.014              0.308   0.201
  Depth of invasion (T1+T2/T3+T4)          2                                      491              0.85 (0.44, 1.66)    0.47                0.636     58.6      0.120           1.000                      
  Lymph node metastasis (Absent/Present)   2                                      491              1.11 (0.80, 1.52)    0.61                0.543     0.0       0.791           1.000                      
  Npas2                                    Differentiation (Moderate+Well/Poor)   4                1129                 1.89 (1.47, 2.43)   4.98      \<0.001   0.0             0.943              0.089   0.003
  TNM (I + II/III + IV)                    5                                      2123             0.79 (0.40, 1.55)    0.70                0.486     86.6      \<0.001         0.221              0.020   
  CLOCK                                    Differentiation (Moderate+Well/Poor)   4                941                  0.87(0.66, 1.16)    0.95      0.342     0.0             0.453              1.000   0.707
  TNM (I + II/III + IV)                    3                                      1142             1.08(0.59, 2.00)     0.26                0.798     80.8      0.006           0.296              0.531   

There was no significant association between low expressions of Cry1, Cry2, CLOCK and clinicopathological parameters. The combined ORs were 0.89 (95%CI: 0.47∼1.68, *Ρ*=0.722) forCry1 and differentiation, 0.86 (95%CI: 0.22∼3.26, *Ρ*=0.825) for Cry1 and invasion depth and 0.55 (95%CI: 0.29∼1.03, *Ρ*=0.062) for Cry1 and lymph node metastasis. The pooled ORs were 1.35 (95%CI: 0.84∼2.15, *Ρ*=0.214) forCry2 and differentiation, 0.85 (95%CI: 0.44∼1.66, *Ρ*=0.636) for Cry2 and invasion depth and 1.10 (95%CI: 0.80∼1.52, *Ρ*=0.543) for Cry2 and lymph node metastasis. The pooled ORs were 0.87 (95%CI: 0.66∼1.16, *Ρ*=0.342) forCLOCK and differentiation, 1.08 (95%CI: (0.59∼2.00, *Ρ*=0.798) forCLOCK and TNM stage.

To explore the heterogeneity among these results, we conducted the subgroup analysis. The results indicated that the correlation between low Per1 expression and differentiation was exhibited in non-IHC group (OR=1.51, 95%CI: 1.10∼2.08, *Ρ*=0.010) and published after 2015 group (OR=1.62, 95%CI: 1.14∼2.30, *Ρ*=0.007) without heterogeneity (*Ι*^2^=0.0%, *Ρ*=0.680 and *Ι*^2^=0.0%, *Ρ*=0.625, respectively). The relationship between low Per2 expression and differentiation was displayed in non-gastrointestinal cancer group (OR=2.82, 95%CI: 1.91∼4.15, *Ρ*\<0.001, *Ι*^2^= 37.2%, *Ρ*=0.173) and published before 2015 group (OR=2.19, 95%CI: 1.66∼2.88, *Ρ*\<0.001, *Ι*^2^=0.0%, *Ρ*=0.606). The correlation between low Per2 expression and [TNM](http://xueshu.baidu.com/usercenter/paper/show?paperid=0ece9213242ab22c830b8fd6a6c52470&site=xueshu_se) was also exhibited in IHC group (OR =4.82, 95%CI: 3.27∼7.08, *Ρ*\<0.001) and published before 2015 group (OR=4.82, 95%CI: 3.27∼7.08, *Ρ*\<0.001) without heterogeneity (^2^=0.0%, *Ρ*=0.908 and *Ι*^2^= 0.0%, *Ρ*=0.908, respectively). Furthermore, the heterogeneity among studies related to low Per2 expression and lymph node metastasis was obviously decreased in non-gastrointestinal cancer group (OR=3.89, 95%CI: 2.59∼5.84, *Ρ*\<0.001, *Ι*^2^=1.4%, *Ρ*=0.363). Additionally, the heterogeneity among studies related to low Per3 expression and differentiation was also decreased in non-gastrointestinal cancer group (*Ι*^2^= 5.6%, *Ρ*=0.276) and IHC group (*Ι*^2^=0.0%, *Ρ*=0.326) ([Table 3](#pone.0233508.t003){ref-type="table"}). These results indicated that the differences in detecting methods, publish years and pathological types might be the source of study heterogeneity.

10.1371/journal.pone.0233508.t003

###### Subgroup analysis results of association between low circadian clock genes expression and clinicopathological and prognostic parameters in cancers.
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  Circadian clock gene                     Clinicopathological parameters         No. of studies   No. of patients      Pooled HR or OR (95%CI)   Z value             P-value       Heterogeneity   Publication bias                         
  ---------------------------------------- -------------------------------------- ---------------- -------------------- ------------------------- ------------------- ------------- --------------- ------------------ ------------- ------- -------
  Per1                                     Overall survival(Low/High)             Chinese          10                   2585                      1.33 (1.02, 1.74)   2.09          0.037           80.0               **\<**0.001   0.592   0.183
  Non-Chinese                              2                                      253              1.52 (1.02, 2.28)    2.05                      0.041               8.6           0.296           1.000                                    
  Gastrointestinal cancer                  7                                      945              1.33 (1.14, 1.55)    3.59                      **\<**0.001         4.2           0.395           1.000              0.528                 
  Non-gastrointestinal cancer              5                                      1893             1.37 (0.86, 2.17)    1.32                      0.188               89.2          **\<**0.001     0.086              0.054                 
  IHC                                      3                                      579              2.22 (1.29, 3.80)    2.89                      0.004               64.4          0.060           1.000              0.509                 
  Non-IHC                                  9                                      2259             1.16 (0.92, 1.46)    1.25                      0.21                69.5          0.001           0.754              0.378                 
  Number of patients ≥100                  9                                      2660             1.38 (1.00, 1.89)    1.98                      0.048               82.1          **\<**0.001     0.348              0.069                 
  Number of patients \<100                 3                                      178              1.30 (0.97, 1.75)    1.78                      0.075               24.0          0.268           1.000              0.784                 
  Published before 2015                    5                                      162              1.66 (1.15, 2.38)    2.72                      0.007               72.3          0.006           0.462              0.202                 
  Published after 2015                     7                                      2028             1.17 (0.85, 1.60)    0.96                      0.335               75.8          **\<**0.001     0.764              0.268                 
  Differentiation (Moderate+Well/Poor)     Chinese                                8                1301                 2.61 (1.39, 4.92)         2.97                0.003         71.3            0.001              0.711         0.757   
  Non-Chinese                              3                                      287              1.23 (0.62, 2.44)    0.60                      0.546               0.0           0.585           0.296              0.061                 
  Gastrointestinal cancer                  4                                      702              2.46 (1.01, 6.04)    1.97                      0.049               70.1          0.018           1.000              0.733                 
  Non-gastrointestinal cancer              7                                      886              2.16 (1.04, 4.51)    2.06                      0.039               62.9          0.013           1.000              0.761                 
  IHC                                      7                                      771              2.95 (1.46, 5.98)    3.01                      0.003               59.5          0.022           0.230              0.148                 
  Non-IHC                                  4                                      817              1.51 (1.10, 2.08)    2.58                      0.01                0.0           0.680           1.000              0.914                 
  Number of patients ≥100                  5                                      1311             2.77 (1.34, 5.74)    2.74                      0.006               81.7          **\<**0.001     0.462              0.412                 
  Number of patients **\<**100             6                                      277              1.76 (0.83, 3.71)    1.47                      0.141               19.5          0.286           1.000              0.473                 
  Published before 2015                    9                                      1007             2.39 (1.24, 4.59)    2.60                      0.009               65.7          0.003           0.466              0.302                 
  Published after 2015                     2                                      581              1.62 (1.14, 2.30)    2.70                      0.007               0.0           0.625           1.000                                    
  Per2                                     Overall survival(Low/High)             Chinese          6                    1940                      1.40 (1.04, 1.89)   2.22          0.026           74.5               0.001         0.060   0.088
  Non-Chinese                              3                                      324              1.74 (1.00, 3.03)    1.96                      0.05                0.0           0.689           0.296              0.137                 
  Gastrointestinal cancer                  4                                      570              1.65 (1.25,2.18)     3.50                      **\<**0.001         0.0           0.851           0.308              0.641                 
  Non-gastrointestinal cancer              5                                      1694             1.36 (0.96, 1.93)    1.75                      0.08                75.7          0.002           0.221              0.114                 
  IHC                                      2                                      376              1.92 (1.24, 2.96)    2.93                      0.003               47.1          0.169           1.000                                    
  Non-IHC                                  7                                      1888             1.24 (0.95, 1.60)    1.59                      0.111               49.3          0.066           0.548              0.215                 
  Number of patients ≥100                  6                                      2102             1.39 (1.05, 1.83)    2.33                      0.02                73.0          0.002           0.133              0.078                 
  Number of patients **\<**100             3                                      162              1.92 (0.84, 4.36)    1.55                      0.122               5.1           0.349           0.296              0.023                 
  Published before 2015                    3                                      578              1.85 (1.42, 2.392)   4.62                      **\<**0.001         0.0           0.370           1.000              0.367                 
  Published after 2015                     6                                      1686             1.15 (0.90, 1.47)    1.10                      0.27                43.1          0.118           0.707              0.379                 
  Differentiation (Moderate+Well/Poor)     Chinese                                7                1104                 2.89 (1.92, 4.35)         5.08                **\<**0.001   57.7            0.028              0.368         0.057   
  Non-Chinese                              2                                      253              0.65 (0.31, 1.37)    1.14                      0.256               0.0           0.621           1.000                                    
  Gastrointestinal cancer                  4                                      537              1.62 (0.58, 4.54)    0.91                      0.363               79.3          0.002           1.000              0.860                 
  Non-gastrointestinal cancer              5                                      820              2.82 (1.91, 4.15)    5.24                      **\<**0.001         37.2          0.173           0.221              0.032                 
  IHC                                      5                                      534              3.92 (1.80, 8.54)    3.45                      0.001               68.2          0.014           1.000              0.054                 
  Non-IHC                                  4                                      823              1.58 (0.89, 2.81)    1.55                      0.12                69.4          0.020           0.734              0.373                 
  Number of patients ≥100                  4                                      1108             1.75 (0.87, 3.50)    1.58                      0.114               78.7          0.003           1.000              0.963                 
  Number of patients **\<**100             5                                      249              3.40 (2.02, 5.71)    4.61                      **\<**0.001         28.2          0.234           1.000              0.595                 
  Published before 2015                    3                                      621              2.19 (1.66, 2.88)    5.60                      **\<**0.001         0.0           0.606           1.000              0.601                 
  Published after 2015                     6                                      736              2.85 (1.23, 6.61)    2.45                      0.014               79.4          **\<**0.001     0.707              0.148                 
  TNM (I + II/III + IV)                    IHC                                    3                228                  4.82 (3.27, 7.08)         7.98                **\<**0.001   0.0             0.908              1.000         0.307   
  Published before 2015                    3                                      228              4.82 (3.27, 7.08)    7.98                      **\<**0.001         0.0           0.908           1.000              0.307                 
  Lymph node metastasis (Absent/Present)   Chinese                                5                514                  3.14 (1.83, 5.40)         4.15                **\<**0.001   71.0            0.008              0.221         0.398   
  Non-Chinese                              2                                      253              1.12 (0.68, 1.83)    0.45                      0.653               0.0           0.942           1.000                                    
  Gastrointestinal cancer                  4                                      537              1.77 (0.76, 4.16)    1.31                      0.189               86.1          **\<**0.001     1.000              0.456                 
  Non-gastrointestinal cancer              3                                      230              3.89 (2.59, 5.84)    6.54                      **\<**0.001         1.4           0.363           0.296              0.294                 
  IHC                                      4                                      474              2.72 (1.39, 5.35)    2.91                      0.004               73.5          0.010           0.735              0.553                 
  Non-IHC                                  3                                      293              1.90 (0.62, 5.80)    1.13                      0.258               87.7          **\<**0.001     1.000              0.749                 
  Number of patients ≥100                  3                                      578              1.59 (0.92, 2.77)    1.65                      0.1                 56.7          0.099           0.296              0.193                 
  Number of patients **\<**100             4                                      189              3.42 (1.89, 6.19)    4.07                      **\<**0.001         61.8          0.049           0.308              0.083                 
  Published before 2015                    2                                      91               2.51 (0.56, 11.19)   1.21                      0.227               83.5          0.014           1.000                                    
  Published after 2015                     5                                      676              2.24 (1.15, 4.34)    2.38                      0.017               80.5          **\<**0.001     1.000              0.743                 
  Per3                                     Differentiation (Moderate+Well/Poor)   Chinese          3                    863                       3.63 (1.67, 7.87)   3.26          0.001           72.3               0.027         1.000   0.312
  Gastrointestinal cancer                  2                                      405              2.27 (0.24, 21.83)   0.71                      0.477               93.3          **\<**0.001     1.000                                    
  Non-gastrointestinal cancer              2                                      660              2.39 (1.56,3.66)     4.01                      **\<**0.001         15.6          0.276           1.000                                    
  IHC                                      2                                      333              5.46 (2.89, 10.31)   5.24                      **\<**0.001         0.0           0.326           1.000                                    
  Non-IHC                                  2                                      732              1.33 (0.46, 3.87)    0.52                      0.604               83.3          0.014           1.000                                    

3. Impact of circadian clock genes expression on overall survival of cancers {#sec014}
----------------------------------------------------------------------------

The association between low expression of circadian clock genes and OS was further explored in this meta-analysis. Low expressions of Per1 and Per2 were related to poor OS in patients with cancers (Per1: HR=1.35, 95%CI: 1.06∼1.72, P=0.014 and Per2: HR =1.43, 95%CI: 1.10∼1.85, P=0.007), with high observed heterogeneity (Per1: *Ι*^2^=77.1%, P\<0.001 and Per2: *Ι*^2^=63.1%, P=0.006) ([Table 4](#pone.0233508.t004){ref-type="table"} and [Fig 5](#pone.0233508.g005){ref-type="fig"}). These results demonstrated that low expressions of Per1 and Per2 were significantly associated with worse prognosis in cancers.

![Forrest plot of hazard ratio (HR) for the association of low Per1 (A) and Per2 (B) expression and overall survival.](pone.0233508.g005){#pone.0233508.g005}

10.1371/journal.pone.0233508.t004

###### Meta-analysis results of association between low circadian clock genes expression and prognosis in cancers.

![](pone.0233508.t004){#pone.0233508.t004g}

  Circadian clock gene   No. of studies   No. of patients   Pooled HR(95%CI)    Z      P-value   Heterogeneity   Publication bias           
  ---------------------- ---------------- ----------------- ------------------- ------ --------- --------------- ------------------ ------- -------
  Per1                   12               2838              1.35 (1.06, 1.72)   2.46   0.014     77.1            \<0.001            0.537   0.119
  Per2                   9                2264              1.43 (1.10, 1.85)   2.68   0.007     63.1            0.006              0.602   0.145
  Per3                   7                2088              1.32 (0.99, 1.76)   1.91   0.056     86.1            \<0.001            0.230   0.033
  Cry1                   8                1706              0.79 (0.54, 1.11)   1.37   0.170     60.8            0.013              0.711   0.849
  Cry2                   9                3245              1.06 (0.82, 1.37)   0.47   0.635     78.1            \<0.001            0.754   0.190
  Npas2                  7                2519              0.85 (0.61, 1.19)   0.93   0.352     86.0            \<0.001            0.548   0.142
  Baml1                  7                1809              1.10 (0.82, 1.49)   0.64   0.519     75.2            \<0.001            0.764   0.438
  CLOCK                  7                2389              1.05(0.74, 1.48)    0.27   0.790     82.3            \<0.001            0.548   0.915

No significant correlation was found between low expression of Per3, Cry1, Cry2, Npas2, Baml1, CLOCK and [OS](http://xueshu.baidu.com/usercenter/paper/show?paperid=0ece9213242ab22c830b8fd6a6c52470&site=xueshu_se) (Per3: HR=1.32, 95%CI: 0.99∼1.76; Cry1: HR=0.79, 95%CI: 0.54∼1.11; Cry2: HR=1.06, 95%CI= 0.82∼1.37; Npas2: HR=0.85, 95%CI: 0.61∼1.19; Baml1: HR=1.10, 95%CI: 0.82∼1.49 and CLOCK: HR=1.05, 95%CI: 0.74∼1.48) ([Table 4](#pone.0233508.t004){ref-type="table"}).

To explain the heterogeneity in OS, subgroup analysis was performed, and the results showed that the heterogeneity among studies related to low Per1 expression and OS was obviously decreased in gastrointestinal cancer group (HR=1.33, 95%CI: 1.14∼1.55, P\<0.001, *Ι*^2^=4.2%, P=0.395) and non-Chinese group (HR=1.52, 95%CI: 1.02∼2.08, P=0.041, *Ι*^2^=8.6%, P=0.296) ([Table 3](#pone.0233508.t003){ref-type="table"}). The heterogeneity among studies related to low Per2 expression and OS was significantly decreased in gastrointestinal cancer group (HR=1.62, 95%CI: 1.25∼2.18, P\<0.001, *Ι*^2^=0.0%, P=0.851), IHC group (HR=1.92, 95%CI: 1.24∼2.96, P=0.003, *Ι*^2^=47.1%, P=0.169) and published before 2015 group (HR=1.85, 95%CI: 1.42∼2.39, P\<0.001, *Ι*^2^=0.0%, P=0.370) ([Table 3](#pone.0233508.t003){ref-type="table"}). The differences in pathological types, populations, detecting methods and publish years might contribute to heterogeneity in these results.

4. Sensitivity analysis and publication bias {#sec015}
--------------------------------------------

Sensitivity analysis was performed to check the stability of statistically significant results. As showed in Figs [6](#pone.0233508.g006){ref-type="fig"}, [7](#pone.0233508.g007){ref-type="fig"} and [8](#pone.0233508.g008){ref-type="fig"}, the pooled ORs or HRs and 95% CIs did not change substantially after removing one study at a time in the comparison between low and high expression of Per1, Per2 and Npas2.However, after removing single study out one by one, the relationship between low expression of Per3 and differentiation become not significant (from OR=2.50, 95%CI: 1.10∼5.66to OR=2.68, 95%CI: 0.65∼11.07) ([Fig 7C](#pone.0233508.g007){ref-type="fig"}). These results suggested that the meta-analysis of Per1, Per2 and Npas2 were reliable and stable. Publication bias was detected by Begg' funnel plot and Egger's test in the current meta-analysis and the shape of the funnel plots seemed symmetrical in Figs [9](#pone.0233508.g009){ref-type="fig"}, [10](#pone.0233508.g010){ref-type="fig"} and [11](#pone.0233508.g011){ref-type="fig"}. Thus publication bias might not have a substantial influence on the result of this meta-analysis.

![Sensitive analysis of low Per1 (A), Per2 (B) expression and overall survival.](pone.0233508.g006){#pone.0233508.g006}

![Sensitive analysis of low Per1 (A), Per2 (B), Per3 (C), Npas2 (D) expression and differentiation.](pone.0233508.g007){#pone.0233508.g007}

![Sensitive analysis of low Per1 expression and depth of invasion (A), low Per2 expression and lymph node metastasis (B),TNM (C).](pone.0233508.g008){#pone.0233508.g008}

![The Begg's funnel plots assessing the publication bias in analyses of the association of low Per1 (A) and Per2 (B) expression and overall survival.](pone.0233508.g009){#pone.0233508.g009}

![The Begg's funnel plots assessing the publication bias in analyses of the association of low Per1 (A), Per2 (B), Per3 (C) and Npas2 (D) expression and differentiation.](pone.0233508.g010){#pone.0233508.g010}

![The Begg's funnel plots assessing the publication bias in analyses of the association of low Per1 expression and depth of invasion (A), low Per2 expression and lymph node metastasis (B), TNM (C).](pone.0233508.g011){#pone.0233508.g011}

Discussion {#sec016}
==========

Meta-analysis is a quantitative statistical method that summarizes results of different studies with the same theme to reach a general conclusion. This approach has been successfully used for evaluation of clinicopathological and prognostic parameters in patients with cancers. Circadian clock genes and gene products generate overt circadian rhythms. The disruption of circadian clock genes expression leads to loss of circadian oscillations, such as loss of the 24 h rest-activity cycle, serum corticosterone level daily rhythms, lymphocyte count and body temperature rhythm, which has been associated with higher tumorigenesis rates, faster tumor growth in humans and animal models \[[@pone.0233508.ref042], [@pone.0233508.ref051]\]. However, the relationship between circadian clock genes expression and clinicopathological and prognostic features of cancers was controversial. Therefore, it is rather necessary to analyze and combine these data to reach a reasonable conclusion. Recently, many studies have demonstrated that low expression of circadian clock genes results in the disruption of the normal circadian rhythm and plays an important role in the development, invasion, and metastasis of many kinds of cancers \[[@pone.0233508.ref003], [@pone.0233508.ref026], [@pone.0233508.ref029], [@pone.0233508.ref039]\], hence, we focused on meta-analyzing the association of low expression of circadian clock genes and cancers. This meta-analysis was the first comprehensive assessment of the association between low circadian clock genes expression and cancer progression and prognosis. Our results showed that low Per1, Per2, Per3 and Npas2 expression played a distinct and crucial role in progression of cancers. Low expressions of Per1 and Per2 could serve as unfavorable indicators for gastrointestinal cancers prognosis.

Inhibition of endogenous Per1 expressionresulted in the abrogation of the ATM/Checkpoint kinase 2 (Chk2) checkpoint pathway and led to less DNA damage-induced apoptosis of cancer cells \[[@pone.0233508.ref052]\]. Similar effects were also seen when Per2 was knockdown in human leukemia cells. Knockdown of Per2led to downregulation of p53 and upregulation of Cylin B1 and c-Myc and promoted tumorigenesis \[[@pone.0233508.ref053]\]. Npas2 had been shown to bind to the c-Mycpromoter and suppress its transcription and lower expression of Npas2 resulted in increased cell growth and cycle progression of tumor cells \[[@pone.0233508.ref004], [@pone.0233508.ref009]\]. These observations concurred with our findings and suggested that low expressions of Per1, Per2 and Npas2 could significantly lead to poor differentiation of cancers through the same underlying mechanism mentioned above. Decreased Perl expression upregulated the expression of matrixmetalloproteinase-2 and increased the cell membrane distribution of laminin receptor 1, thereby enhanced tumor cells invasion \[[@pone.0233508.ref054], [@pone.0233508.ref055]\]. This result might partially account for why low Per1 expression was significantly correlated with deeper invasion depth. The epithelial-to-mesenchymal transition (EMT) is a key step in cancer progression and enables cancer cell metastasis. Low expression of Per2 led to the activation of EMT genes TWIST1 and SLUG and promoted cancer metastasis \[[@pone.0233508.ref056]\]. Therefore, low expression of Per2 might result in further metastasis as our meta-analysis indicated. Since low expressions of Per1 and Per2 were correlated with poorer tumor cell differentiation, deeper invasion depth and worse metastasis, it was reasonable to suppose that low expression of Per1 and Per2 might result in poorer OS, as studies pointed out \[[@pone.0233508.ref003], [@pone.0233508.ref011]--[@pone.0233508.ref019]\]. As expected, the pooled HR results in our study indicated that patients with low expression of Per1 or Per2 had a shorter OS.

Intestinal cell growth, proliferation, differentiation and gut microbiome had a daily rhythm orchestrated by circadian clock genes \[[@pone.0233508.ref057], [@pone.0233508.ref058]\]. Per1 and Per2 were expressed rhythmically throughout the gastrointestinal tract and had been shown to coordinate gastrointestinal functions such as motility, cell proliferation and migration, and regulate host gut microbiota rhythms \[[@pone.0233508.ref059], [@pone.0233508.ref060]\]. The deregulated expression of Per1 and Per2 was correlated with the host and microbiota circadian rhythms disruption and had been thought to be associated with gastrointestinal cancer progression and prognosis \[[@pone.0233508.ref005], [@pone.0233508.ref012], [@pone.0233508.ref013], [@pone.0233508.ref015], [@pone.0233508.ref016], [@pone.0233508.ref029], [@pone.0233508.ref030]\]. Circadian rhythms controlled by Per1 and Per2 might have stronger and synergistic influence on the gastrointestinal cancer progression, therefore, the heterogeneity among studies which focused on gastrointestinal cancers prognosis [was](https://www.baidu.com/link?url=qEHeLeKs0I_4Mx1AaaFGCcqD6JoB-yp6sOpMfBd2WxtE-mOM0d8AgBD6Y_R_A6Ss9FUZ40pYlp7hQNGdjEGRR04f8JY69cUcxQ4na1p8qf3&wd=&eqid=97d636e1002347b9000000065dee5198) obviously reduced. Further studies are required to investigate the specific mechanisms involved. The heterogeneity among low Per2 expression and differentiation decreased in non-gastrointestinal cancer group (HR=2.82, 95%CI=1.91∼4.15, P\<0.001, *I*^*2*^= 37.2%, P=0.173), whereas the heterogeneity of low Per2 expression and [OS](http://xueshu.baidu.com/usercenter/paper/show?paperid=0ece9213242ab22c830b8fd6a6c52470&site=xueshu_se) disappeared in gastrointestinal cancer group (HR=1.62, 95% CI=1.25∼2.18, P\<0.001, *I*^*2*^=0.0%, P=0.851). These two results are inconsistent and the reason for this appeared to be that the ORs varied significantly in gastrointestinal cancers and could not reveal the true state since the time variable was not included in the OR analysis. Further studies are needed to illustrate this inconsistency. No association between the low expression of Cry1, Cry2 and Bmal1 and prognosis of cancers was found. The controversial and inconsistent prognostic results in those studies might be the reason for these negative findings \[[@pone.0233508.ref006], [@pone.0233508.ref024], [@pone.0233508.ref025], [@pone.0233508.ref032], [@pone.0233508.ref033], [@pone.0233508.ref045], [@pone.0233508.ref048], [@pone.0233508.ref051]\], and future large cohorts studies are needed to fully evaluate the relationship between the expression of these clock genes and cancer prognosis.

Although some studies focused on other circadian clock genes (such as casein kinase 1ε (CK1ε), receptor subfamily 1 group D member 1/2 (NRD1/2), RAR-related orphan receptor A and B (RORA/B), timeless (Tim) and timeless-interacting protein (Tipin)) and cancers prognosis, these data were not sufficient to meta-analyze HR or OR of these circadian clock genes \[[@pone.0233508.ref013], [@pone.0233508.ref023], [@pone.0233508.ref029], [@pone.0233508.ref049]\]. The rhythmic expression of clock genes is critical for cancer cell growth, however, only two studies have focused on cosinor analysis of circadian gene expression levels in pancreatic cancer cell lines and tumor bearing mice \[[@pone.0233508.ref040], [@pone.0233508.ref061]\]. Therefore, the rhythmic expression of circadian clock genes was not included in this meta-analysis.

Several limitations do exist in our study. First, potentially relevant unpublished papers and studies published in non-English or Chinese were not included in this meta-analysis, thereby the reliability of our results might be weakened. Second, most of the population in our studies were from Asia, so the conclusion reliability of this meta analysis might also be weakened by this ethic disparity and furtherstudies included more European and American are needed. Third, the sample sizes of the studies ranged from 34 to 737 patients and could be the source of heterogeneity as displayed in [Table 4](#pone.0233508.t004){ref-type="table"}. Fourth, the estimating HRs and their 95% CIs from Kaplan-Meier curves might be less reliable because of the inaccuracy method in extracting survival data. Fifth, we also thought that the difference in published year and detection assays for circadian clock genes expression should be taken into consideration. To the best of our knowledge, immunohistochemistry had been widely used for detecting the expression of circadian clock genes, however, recent researchers preferred performing qRT-PCR or microarray to evaluate circadian clock genes expression. These differences might contribute to the methodological heterogeneity.

Conclusions {#sec017}
===========

In conclusion, our meta-analysis provided evidence that low Per1, Per2and Npas2 expression played a distinct and crucial role in progression of cancers. Low expressions of Per1 and Per2 could serve as unfavorable indicators for cancers prognosis, especially for gastrointestinal cancers. However, well designed, larger-size and higher-quality cohort studies are needed to investigate the precise impact of Per1, Per2and Npas2 on the pathobiological behaviors and prognosis of cancers.
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